Market Overview

Piper Sees "Meaningful Utility" from GW Phamaceuticals CBD, Reiterates Overweight Rating

Related GWPH
GW Pharma Continues To Move On Takeover Speculation
GW Pharma Set To Fly High: Goldman Sachs Starts Coverage At Buy, Sees 42% Upside

In a report published Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on GW Pharmaceuticals plc (NASDAQ: GWPH) and raised the price target from $77.00 to $97.00.

Schimmer mentioned new checks with specialists who were convinced that CBD has “meaningful utility” for seizure patients. The analyst commented that CBD and THC have been reported to benefit individuals with migraine headaches and autism.

The analyst wrote that after reviewing Dravet studies, the “finding is consistent with what we have heard from specialists, suggesting the Epidiolex Phase III studies may be overpowered, and thereby substantially improving the probability that the 'views from the field' represent a true drug effect.”

GW Pharmaceuticals closed at $57.71 on Thursday. Shares have traded as high as $64.73, up 12.16% on Friday. This has been the biggest intraday gain since January 9.

Latest Ratings for GWPH

Oct 2016Leerink SwannAssumesOutperform
Sep 2016Morgan StanleyMaintainsOverweight
Sep 2016Cantor FitzgeraldMaintainsBuy

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Joshua Schimmer Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (GWPH)

View Comments and Join the Discussion!